Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyowa Kirin Completes New Plant for Investigational Antibodies
March 29, 2010
- Toho to Acquire 2 More Dispensing Pharmacy Chains
March 29, 2010
- Cabazitaxel Increases OS in Advanced Hormone-Refractory Prostate Cancer
March 29, 2010
- Gifu Pref. Orders Taiyo Yakuhin's Takayama Plant to Stop Operation
March 29, 2010
- Sutent Fails to Meet Primary Endpoint in PIII for Advanced Breast Cancer
March 29, 2010
- Towa to Increase Its Number of MRs to 450
March 29, 2010
- Ghrelin Attracts Attention at Protein Mall Kansai
March 29, 2010
- PMDA to Review Applications for Priority Products within 10 Months
March 29, 2010
- 74th JCS Annual Scientific Meeting
March 29, 2010
- Value-Based Generics Use Rate of 6.6% Reported by Kyokai Kenpo
March 29, 2010
- Discussions Started on Vaccination Act Amendment
March 29, 2010
- Takata Seiyaku Takes Over 5 Shionogi Brands
March 29, 2010
- Osaka Pref. Demands That Korosho Accept Return of Flu Vaccines
March 29, 2010
- No Serious Concern about Domestic Flu Vaccines
March 29, 2010
- Pharmacists Should Provide More Personalized Medication Guidance: Mr Isobe
March 29, 2010
- In the Blink of an Eye
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
March 29, 2010
- Astellas to Continue to Directly Address OSI's Stockholders
March 29, 2010
- Takeda Withdraws MAA for Actos + Metformin Once-Daily Combination
March 29, 2010
- Sapporo City to Subsidize Hib Vaccines from FY2010
March 29, 2010
- Erbitux to Be Approved for Use in 1st-Line Therapy
March 29, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…